Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

With its €380 million takeout of Dublin-based Inflazome, Roche is continuing the rush of pharmas targeting inflammasome companies in a deal that leaves NodThera as the last company standing among the first crop of high profile venture-backed biotechs with NLRP3 inhibitors.

According to Forbion’s Marco Boorsma, the decision to sell Inflazome Ltd. to Roche (SIX:ROG; OTCQX:RHHBY) just four years after its launch was partly based on the breadth of opportunities that could be pursued with an NLRP3 inhibitor...